Impacto das vacinas contra a COVID-19 em pessoas idosas: relação entre doses, fabricantes e mortalidade

Caroline Camilo da Silva; Gustavo Diego Magno; Silvia Carla da Silva André Uehara

doi:10.36517/2175-6783.20252694780

Autores

Caroline Camilo da Silva Universidade Federal de São Paulo https://orcid.org/0009-0004-4974-5879
Gustavo Diego Magno Universidade Federal de São Carlos https://orcid.org/0000-0003-3656-9170
Silvia Carla da Silva André Uehara Universidade Federal de São Carlos https://orcid.org/0000-0002-0236-5025

DOI:

https://doi.org/10.36517/2175-6783.20252694780

Palavras-chave:

COVID-19; Vacinação; Mortalidade; Idoso.

Resumo

Objetivo: analisar a relação entre o número de doses e fabricantes das vacinas contra a COVID-19 e o impacto na mortalidade de pessoas idosas. Métodos: estudo ecológico analítico, realizado com pessoas com 60 anos ou mais. Os dados foram obtidos nas páginas oficiais Vacinômetro e Painel Coronavírus e analisados por meio da estatística descritiva e modelo linear generalizado com distribuição binomial negativa. Resultados: o coeficiente de mortalidade por COVID-19 foi 498,360/100000 pessoas idosas no período anterior ao início da vacinação; e, posteriormente, foi de 327,880/100.000 pessoas idosas. Destaca-se que a vacina da Janssen apresentou diminuição de 54,6% no risco de óbito nesse grupo populacional. Conclusão: a análise da relação entre o número de doses e os fabricantes das vacinas contra a COVID-19 e o impacto na mortalidade evidenciou um resultado positivo, com redução expressiva da taxa de mortalidade anual da doença entre a população idosa após o início da vacinação. Contribuições para a prática: o estudo sinaliza a importância da vacinação contra a COVID-19 nos idosos, destacando a relevância da adesão às doses de reforço para que essa população continue protegida.

Downloads

Os dados de download ainda não estão disponíveis.

Referências

Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. doi: https://doi.org/10.1016/j.arr.2020.101205

Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020;13(12):e37–e42. doi: https://doi.org10.1016/j.jiph.2020.07.014

Fleury S, Fava VMD. Vaccine against COVID-19: arena of the Brazilian federative dispute. Saúde Debate. 2022;46(spe1):248-64. doi: https://doi.org/10.1590/0103-11042022E117

Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, et al. Safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N Engl J Med. 2021;384(23):2187-201. doi: https://doi.org/10.1056/NEJMoa2101544

Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021;373:n1088. doi: https://doi.org/10.1136/bmj.n1088

Santos CVBD, Valiati NCM, Noronha TG, Porto VBG, Pacheco AG, Freitas LP, et al. The effectiveness of COVID-19 vaccines against severe cases and deaths in Brazil from 2021 to 2022: a registry-based study. Lancet Reg Health Am. 2023;20:100465. doi: https://doi.org/10.1016/j.lana.2023.100465

Orellana JDY, Cunha GM, Marrero L, Leite IC, Domingues CMAS, Horta BL. Cambios en el patrón de internamientos y óbitos por COVID-19 tras una elevada vacunación de ancianos en Manaos, Amazonas, Brasil. Cad Saúde Pública. 2022;38(5):e00133422. doi: https://dx.doi.org/10.1590/0102-311XPT192321

Wan EYF, Mok AHY, Yan VKC, Chan CIY, Wang B, Lai FTT, et al. Effectiveness of BNT162b2 and CoronaVac vaccinations against SARS-CoV-2 omicron infection in people aged 60 years or above: a case–control study. J Travel Med. 2022;29(8):taac119. doi: https://doi.org/10.1093/jtm/taac119

World Health Organization (WHO). Statement on the antigen composition of COVID-19 vaccines [Internet]. 2023 [cited Feb 21, 2025]. Available from: https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines

Ministério da Saúde (BR). Secretaria de Vigilância em Saúde e Ambiente. Nota técnica conjunta nº 83/2025-DPNI/SVSA/MS [Internet]. 2025 [cited Feb 21, 2025]. Available from: https://sbim.org.br/images/n9eax63fjy.pdf

Panahi Y, Gorabi AM, Talaei S, Beiraghdar F, Akbarzadeh A, Tarhriz V et al. An overview on the treatments and prevention against COVID-19. Virol J. 2023;20(1):23. doi: https://doi.org/10.1186/s12985-023-01973-9

Banho CA, Sacchetto L, Campos GRF, Bittar C, Possebon FS, Ullmann LS, et al. Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. Commun Med. 2022;2:41. doi: https://doi.org/10.1038/s43856-022-00108-5

Medronho RA. Epidemiology. São Paulo: Atheneu; 2009.

Ministério da Saúde (BR). Vacinômetro COVID-19 [Internet]. 2025 [cited Mar 26, 2025]. Available from: https://infoms.saude.gov.br/extensions/SEIDIGI_DEMAS_Vacina_C19/SEIDIGI_DEMAS_Vacina_C19.html

Ministério da Saúde (BR). Agência Nacional de Vigilância Sanitária. Vacinas – COVID-19 [Internet]. Plano Nacional de Operacionalização da Vacinação contra a COVID-19 [Internet]. 2021 [cited Jan 3, 2025]. Available from: https://sbim.org.br/images/files/notas-tecnicas/plano-vacinao-covid19-ed5-17mar21-cgpni.pdf

Ranzani OT, Hitchings MDT, Dorion M, D’Agostini TL, Paula RC, Paula OFP, et al. Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study. BMJ. 2021;373:n2015. doi: https://doi.org/10.1136/bmj.n2015

Agência Nacional de Vigilância Sanitária (Anvisa). Vacinas - Covid-19 [Internet]. 2024 [cited Jan 3, 2025]. Available from: https://www.gov.br/anvisa/pt-br/assuntos/campanhas/coronavirus/vacinas

Kupek E. Low COVID-19 vaccination coverage and high COVID-19 mortality rates in Brazilian elderly. Rev Bras Epidemiol. 2021;24:e200089. doi: https://doi.org/10.1590/1980-549720210041

Zheng C, Shao W, Chen X, Yu J, Zhang Y, Yang J. Clinical characteristics and outcomes of patients with COVID-19 receiving outpatient or inpatient care in a large cohort in Shanghai, China. JAMA Intern Med. 2022;182(5):576-84. doi: https://doi.org/10.1016/j.ijid.2021.11.009

Whitaker HJ, Tsang RS, Byford R, Andrews NJ, Sherlock J, Pillai PS, et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response among individuals in clinical risk groups. Rev J Infect. 2022;84(5):675-83. doi: https://doi.org/10.1016/j.jinf.2021.12.044

Moline HL. Effectiveness of COVID-19 vaccines in preventing hospitalization among adults aged ≥65 years — COVID-NET, 13 states, February–April 2021. MMWR Morb Mortal Wkly Rep. 2021;70(32):1088-93. doi: http://dx.doi.org/10.15585/mmwr.mm7032e3

Delaunay CL, Mazagatos C, Martínez-Baz I, Túri G, Goerlitz L, Domegan L, et al. COVID-19 vaccine effectiveness in autumn and winter 2022 to 2023 among older Europeans. JAMA Netw Open. 2024;7(7):e2419258. doi: https://doi.org/10.1001/jamanetworkopen.2024.19258

Kislaya I, Machado A, Magalhães S, Rodrigues AP, Franco R, Leite PP, et al. COVID-19 mRNA vaccine effectiveness (second and first booster dose) against hospitalisation and death during Omicron BA.5 circulation: cohort study based on electronic health records, Portugal, May to July 2022. Eurosurveillance. 2022;27(37):2200697. doi: https://dx.doi.org/10.2807/1560-7917.ES.2022.27.37.2200697

Graña C, Ghosn L, Evrenoglou T, Jarde A, Minozzi S, Bergman H, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst Rev. 2022;2022(12):1465-858. doi: https://doi.org/10.1002/14651858.CD015477

Borges LCR, Marcon SS, Brito GS, Terabe M, Pleutim NI, Mendes AH, et al. Adherence to Covid-19 vaccination during the pandemic: the influence of fake news. Rev Bras Enferm. 2024;77:e20230284. doi: https://doi.org/10.1590/0034-7167-2023-0284pt

Poli P, Ribeiro AC, Uehara SCSA. Impact of vaccination on COVID-19 morbidity and mortality among aged people. Rev Rene. 2024;25:e93302. doi: https://doi.org/10.15253/2175-6783.20242593302

Galhardi CP, Freire NP, Fagundes MCM, Minayo MCS, Cunha ICKO. Fake news and vaccine hesitancy in the COVID-19 pandemic in Brazil. Ciênc Saúde Coletiva. 2022;27(5):1345-58. doi: https://doi.org/10.1590/1413-81232022275.24092021

Vasconcelos DA, Santos AM, Nascimento JC, Silva CTS, Menezes AF, Barreiro MSC. Educational interventions for the prevention and management of adverse events following immunization: a systematic review. Ciênc Saúde Coletiva. 2024;29(7):e02242024. doi: http://dx.doi.org/10.1590/1413-81232024297.02242024

Inoue LH, Baccon WC, Pesce GB, Pereira ND, Silva IVTC, Salci MA, et al. Prevalência e fatores associados ao óbito de idosos hospitalizados por COVID-19 no estado do Paraná. Rev Esc Enferm USP. 2024;57:e20230036. doi: https://dx.doi.org/10.1590/1980-220X-REEUSP-2023-0036pt

Araújo SR, Almeida JFF, Rodrigues LF, Machado EL. Preventable COVID-19 cases and deaths by alternative vaccination and non-pharmacological intervention policies in Brazil. Rev Bras Epidemiol. 2023;26:e230054. doi: https://doi.org/10.1590/1980-549720230054